SUBSCRIBE TO OUR RSS
Experimental therapies granted breakthrough designation status from the U.S. Food and Drug Administration.
The Burrill Report
June 21, 2013
[Please login to post comments]
AbbVie Terminates Shire Acquisition, But M&A Activity Remains Brisk
Total life sciences transactions through first 10 months of 2014 reach $253.3 Billion, says Burrill Media
U.S. Government’s Effort to Quell Tax-Driven Acquisitions Could Slow Life Sciences Dealmaking
Nearly half of dollar volume of M&A activity in 2014 involved inversions, says Burrill Media
Life Sciences M&A Activity Sets Annual Record with $8.3B Roche Agreement to buy Intermune, Burrill Media Reports
Fitness and Personal Health Apps Could Pose Privacy Nightmare
Senator Schumer says patients’ data could be sold to third parties without their knowledge.
Intel and Fox Foundation Team to Use Smartwatches to Track Parkinson's Patients
Data from wearable devices has potential to improve monitoring and treatment.
Otonomy Raises $100M in Upsized IPO
Seventy-seven life sciences companies raised $5.8 billion through IPOs by mid-August.
Payers Look to Curb Spending on Specialty Drugs
Podcast: August 18, 2014
Sanofi Licenses Rights to MannKind’s Afrezza for Up to $925M
After many years of struggling, biotech lands marketing partner for inhaled insulin.
New System for Classifying Cancer Could Change the Way Drugs Are Developed
Largest cancer genetic analysis reveals tumor subtype correlated to cell type rather than tissue type.
Juno Therapeutics Fills Its Coffers with Another $134M
Funding for the biotech startup in hot CAR T-cell therapy space tops $300 million.
Tweets from @burrillreport/biobuzz
Copyright 2014 Burrill & Company.
FACEBOOK AND TWITTER